Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#21 / 183 Total
APPN - Appian Corp - Stock Price Chart
TickerAPPN [NASD, RUT]
CompanyAppian Corp
CountryUSA
IndustrySoftware - Infrastructure
Market Cap2.24BEPS (ttm)-1.47
P/E-EPS this Y0.06%
Forward P/E-EPS next Y83.70%
PEG-EPS past 5Y-13.88%
P/S4.00EPS next 5Y-
P/B-EPS Q/Q11.12%
Dividend-Sales Q/Q10.80%
Insider Own44.76%Inst Own44.71%
Insider Trans-9.73%Inst Trans3.34%
Short Float5.65%EarningsMay 02/b
Analyst Recom2.33Target Price39.56
Avg Volume564.04K52W Range30.87 - 54.26
Appian Corp. engages in the provision of business process management (BPM) solutions. Its products include BPM software, case management, mobile application development, and platform-as-a-service. The company was founded by Matthew Wheeler Calkins, Robert Charles Kramer, Marc Wilson, and Michael Beckley in 1999 and is headquartered in McLean, VA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Abdiel Capital Advisors, LP10% OwnerFeb 21 '24Sale32.44400,00012,976,0005,890,304Feb 23 04:23 PM
Lynch Mark StevenDirectorJan 05 '24Option Exercise0.001,392040,503Jan 08 04:02 PM
Abdiel Capital Advisors, LP10% OwnerJan 04 '24Sale33.40248,0008,283,6806,290,304Jan 04 06:36 PM
Abdiel Capital Advisors, LP10% OwnerJan 03 '24Sale33.5729,126977,7106,538,304Jan 04 06:36 PM
Abdiel Capital Advisors, LP10% OwnerJan 02 '24Sale35.5644,0141,565,1486,567,430Jan 04 06:36 PM
FBLG - FibroBiologics Inc - Stock Price Chart
TickerFBLG [NASD]
CompanyFibroBiologics Inc
CountryUSA
IndustryBiotechnology
Market Cap219.88MEPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B151.42EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own18.87%Inst Own0.00%
Insider Trans0.00%Inst Trans-
Short Float0.02%Earnings-
Analyst Recom-Target Price-
Avg Volume92.12K52W Range6.53 - 55.00
FibroBiologics, Inc. engages in the development and commercialization of cell therapies. It focuses on treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The firm's product pipeline includes CybroCell, CYMS101, CYWC628, TCB190, and CYTER915. The company was founded by Peter O'Heeron on April 8, 2021 and is headquartered in Houston, TX.
VTVT - vTv Therapeutics Inc - Stock Price Chart
TickerVTVT [NASD]
CompanyvTv Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap57.59MEPS (ttm)-5.06
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y18.96%
P/S-EPS next 5Y-
P/B-EPS Q/Q-2766.15%
Dividend-Sales Q/Q-100.00%
Insider Own65.60%Inst Own5.17%
Insider Trans0.00%Inst Trans-54.67%
Short Float3.43%EarningsMar 13/b
Analyst Recom1.00Target Price160.00
Avg Volume68.77K52W Range7.38 - 39.60
vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and the Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.
ETSY - Etsy Inc - Stock Price Chart
TickerETSY [NASD, S&P 500]
CompanyEtsy Inc
CountryUSA
IndustryInternet Retail
Market Cap6.95BEPS (ttm)2.19
P/E27.01EPS this Y12.44%
Forward P/E20.66EPS next Y13.86%
PEG1.20EPS past 5Y29.72%
P/S2.52EPS next 5Y22.60%
P/B-EPS Q/Q-10.38%
Dividend-Sales Q/Q0.79%
Insider Own0.90%Inst Own102.46%
Insider Trans-5.97%Inst Trans-3.76%
Short Float13.45%EarningsMay 01/a
Analyst Recom2.62Target Price70.40
Avg Volume3.66M52W Range58.20 - 102.81
Etsy, Inc. engages in the operation of an online marketplace. It offers handmade products such as shoes, clothing, bags, and accessories. It operates through the following segments: Etsy, Reverb, Depop, and Elo7. The company was founded in 2005 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Buckley MerileeCHIEF ACCOUNTING OFFICERApr 03 '24Sale65.041,671108,6822,827Apr 03 05:20 PM
Daniel NicholasCHIEF PRODUCT OFFICERApr 01 '24Option Exercise0.0012,284025,422Apr 03 04:49 PM
Glaser Rachel CCHIEF FINANCIAL OFFICERApr 01 '24Option Exercise0.0021,345085,686Apr 03 04:52 PM
Kumar RachanaCHIEF TECHNOLOGY OFFICERApr 01 '24Option Exercise0.008,390023,207Apr 03 04:54 PM
MOSKOWITZ RAINACHIEF OPERATING OFFICERApr 01 '24Option Exercise0.0015,992044,200Apr 03 04:55 PM
NWGL - Nature Wood Group Ltd ADR - Stock Price Chart
TickerNWGL [NASD]
CompanyNature Wood Group Ltd ADR
CountryChina
IndustryLumber & Wood Production
Market Cap403.91MEPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own-Inst Own0.00%
Insider Trans-Inst Trans-
Short Float0.04%EarningsFeb 14/b
Analyst Recom-Target Price-
Avg Volume92.50K52W Range3.37 - 21.97
Nature Wood Group Ltd. is a holding company, which engages in forest management, harvesting and down-stream wood processing and distribution of logs, decking, flooring, and sawn timber products. It operates through the Direct Purchase and ODM, and Manufacturing Segments. The Direct Purchase and ODM segment represent sourcing of live wood and owning designed design on wood products for sales to end customers. The Manufacturing segment is involved in manufacturing decking, flooring, or sawn timbers. The company was founded on September 22, 2011 and is headquartered in Macau, China.
QRVO - Qorvo Inc - Stock Price Chart
TickerQRVO [NASD, S&P 500]
CompanyQorvo Inc
CountryUSA
IndustrySemiconductors
Market Cap9.24BEPS (ttm)-0.73
P/E-EPS this Y-1.95%
Forward P/E12.10EPS next Y29.66%
PEG-EPS past 5Y-
P/S2.45EPS next 5Y10.00%
P/B2.54EPS Q/Q102.00%
Dividend-Sales Q/Q48.73%
Insider Own0.68%Inst Own90.10%
Insider Trans-3.56%Inst Trans-3.33%
Short Float2.27%EarningsMay 01/a
Analyst Recom2.71Target Price109.42
Avg Volume1.25M52W Range80.62 - 121.65
Qorvo, Inc. provides semiconductor solutions for RF and power. The firm combines product and technology leadership, systems-level expertise, and global manufacturing scale to quickly solve its customers' most complex technical challenges. Qorvo serves diverse high-growth segments of large global markets, including consumer electronics, smart home/IoT, automotive, EVs, battery-powered appliances, network infrastructure, healthcare, and aerospace/defense. It operates through the following segments: High Performance Analog (HPA), Connectivity and Sensors Group (CSG), and Advanced Cellular Group (ACG). The HPA segment supplies RF and power management solutions for infrastructure, defense and aerospace, automotive power, and other markets. The CSG segment supplies connectivity and sensor components and systems featuring multiple technologies such as UWB, Matter, Bluetooth Low Energy, Zigbee, Thread, Wi-Fi, cellular IoT and MEMS-/BAW-based sensors. The ACG segment supplies cellular RF solutions for smartphones, wearables, laptops, tablets, and various other devices. The company was formed following the merger of RF Micro Devices, founded in 2015, and TriQuint Semiconductor, incorporated in 1981. It is headquartered in Greensboro, NC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CREVISTON STEVEN ESVP, Connectivity & SensorsMar 01 '24Sale120.003,000360,00077,552Mar 05 04:10 PM
Chesley PhilipSVP, High Performance AnalogFeb 15 '24Sale114.004,253484,84225,286Feb 16 05:05 PM
FEGO PAUL JSVP, Global OperationsFeb 15 '24Sale114.003,027345,07829,705Feb 16 05:07 PM
Harrison GinaVP and Corporate ControllerFeb 15 '24Sale114.0035440,35618,442Feb 16 05:06 PM
CREVISTON STEVEN ESVP, Connectivity & SensorsDec 14 '23Sale110.003,000330,00080,552Dec 15 04:07 PM
LEXX - Lexaria Bioscience Corp - Stock Price Chart
TickerLEXX [NASD]
CompanyLexaria Bioscience Corp
CountryCanada
IndustryBiotechnology
Market Cap38.67MEPS (ttm)-1.13
P/E-EPS this Y53.96%
Forward P/E-EPS next Y4.30%
PEG-EPS past 5Y18.43%
P/S113.74EPS next 5Y-
P/B5.70EPS Q/Q79.57%
Dividend-Sales Q/Q42.89%
Insider Own12.93%Inst Own9.93%
Insider Trans0.00%Inst Trans9.21%
Short Float3.88%Earnings-
Analyst Recom1.00Target Price10.00
Avg Volume510.40K52W Range0.65 - 6.85
Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. Its products can be used with APIs fat-soluble vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) pain medications, hormones, phosphodiesterase inhibitors, antivirals, nicotine and its analogs, and all cannabinoids including tetrahydrocannabinol (THC) for therapeutic indications, as well as hypertension, SARS-CoV-2/COVID-19, and HIV/AIDS. It operates through the following segments: IP Licensing, B2B Product, Research and Development, and Corporate. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.
HIPO - Hippo Holdings Inc - Stock Price Chart
TickerHIPO [NYSE, RUT]
CompanyHippo Holdings Inc
CountryUSA
IndustryInsurance - Specialty
Market Cap463.25MEPS (ttm)-10.07
P/E-EPS this Y71.37%
Forward P/E-EPS next Y49.13%
PEG-EPS past 5Y-
P/S1.82EPS next 5Y-
P/B1.32EPS Q/Q51.02%
Dividend-Sales Q/Q113.82%
Insider Own48.15%Inst Own26.78%
Insider Trans-0.14%Inst Trans37.51%
Short Float9.29%EarningsMay 02/b
Analyst Recom1.40Target Price23.56
Avg Volume205.44K52W Range6.64 - 25.49
Hippo Holdings, Inc. is a home protection company which provides a new standard of care and protection for homeowners. It makes homes safer and better protected so customers spend less time worrying about the burdens of homeownership and more time enjoying their homes. The company harnesses real-time data, smart home technology, and a growing suite of home services to create an integrated home protection platform. It was founded by Assaf Wand on January 10, 2015 and is headquartered in Palo Alto, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Harry YuvalChief Revenue OfficerMar 22 '24Option Exercise6.4513,18685,090160,100Mar 26 04:10 PM
Harry YuvalChief Revenue OfficerMar 22 '24Sale17.2014,938256,883145,162Mar 26 04:10 PM
Badia AnirudhChief Accounting OfficerMar 11 '24Sale18.391,73531,906122,454Mar 13 05:19 PM
NICHOLS JOHN DRAKEDirectorAug 21 '23Buy10.8324,141261,33650,000Aug 21 05:30 PM
NICHOLS JOHN DRAKEDirectorAug 17 '23Buy10.255,43255,67825,859Aug 21 05:30 PM
SMMT - Summit Therapeutics Inc - Stock Price Chart
TickerSMMT [NASD, RUT]
CompanySummit Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap2.85BEPS (ttm)-0.17
P/E-EPS this Y74.75%
Forward P/E-EPS next Y-20.00%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B64.46EPS Q/Q95.68%
Dividend-Sales Q/Q-
Insider Own88.17%Inst Own4.64%
Insider Trans0.04%Inst Trans-29.21%
Short Float27.58%EarningsMay 01/b
Analyst Recom1.00Target Price8.00
Avg Volume2.23M52W Range1.44 - 5.22
Summit Therapeutics, Inc. a biopharmaceutical company, which discovers, develops, and commercializes medicines to treat infectious diseases. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Menlo Park, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Zanganeh MahkamChief Executive OfficerMar 27 '24Buy3.7254,321201,87424,923,800Mar 27 08:28 PM
Zanganeh MahkamChief Executive OfficerMar 27 '24Buy3.7226,00096,720520,814Mar 27 08:28 PM
Dhingra AnkurChief Financial OfficerMar 26 '24Buy3.75100,000375,000354,958Mar 27 08:27 PM
Zanganeh MahkamChief Executive OfficerMar 26 '24Buy3.7530,000112,50030,000Mar 27 08:28 PM
Dhingra AnkurChief Financial OfficerDec 13 '23Buy2.1720,40044,254254,958Dec 13 04:49 PM
AKTX - Akari Therapeutics Plc ADR - Stock Price Chart
TickerAKTX [NASD]
CompanyAkari Therapeutics Plc ADR
CountryUSA
IndustryBiotechnology
Market Cap9.73MEPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q15.04%
Dividend-Sales Q/Q-
Insider Own0.40%Inst Own4.41%
Insider Trans0.00%Inst Trans-
Short Float0.01%EarningsApr 01/b
Analyst Recom1.00Target Price80.00
Avg Volume16.10K52W Range1.08 - 5.50
Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in Boston, MA.
123456781019